RxSightRXST
RXST
About: RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.
Employees: 498
0
Funds holding %
of 7,323 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
3,444% more call options, than puts
Call options by funds: $8.04M | Put options by funds: $227K
94% more repeat investments, than reductions
Existing positions increased: 93 | Existing positions reduced: 48
1.96% more ownership
Funds ownership: 87.65% [Q4 2024] → 89.61% (+1.96%) [Q1 2025]
9% less funds holding
Funds holding: 212 [Q4 2024] → 192 (-20) [Q1 2025]
25% less capital invested
Capital invested by funds: $1.21B [Q4 2024] → $916M (-$298M) [Q1 2025]
43% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 42
67% less funds holding in top 10
Funds holding in top 10: 3 [Q4 2024] → 1 (-2) [Q1 2025]
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$9
13%
upside
Avg. target
$11
38%
upside
High target
$22
176%
upside
7 analyst ratings
1 positive
14%
5 neutral
71%
1 negative
14%
Morgan Stanley Patrick Wood | 13%upside $9 | Equal-Weight Downgraded | 15 Jul 2025 |
Jefferies Young Li | 13%upside $9 | Hold Downgraded | 10 Jul 2025 |
B of A Securities Craig Bijou | 13%upside $9 | Underperform Maintained | 9 Jul 2025 |
Piper Sandler Adam Maeder | 25%upside $10 | Neutral Maintained | 9 Jul 2025 |
Stifel | 13%upside $9 | Hold Maintained | 9 Jul 2025 |
Financial journalist opinion
Based on 72 articles about RXST published over the past 30 days
Neutral
PRNewsWire
4 hours ago
RxSight, Inc. (RXST) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
BENSALEM, Pa. , July 30, 2025 /PRNewswire/ -- The Law Offices of Howard G.
Neutral
PRNewsWire
6 hours ago
RXST Class Action Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the RxSight, Inc. Class Action
SAN DIEGO , July 30, 2025 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired RxSight, Inc. (NASDAQ: RXST) securities between November 7, 2024 and July 8, 2025. RxSight is a commercial-stage medical technology company, engaged in the research and development, manufacture, and sale of light adjustable intraocular lenses ("LAL") used in cataract surgery in the United States.
Neutral
GlobeNewsWire
7 hours ago
RXST INVESTORS: RxSight, Inc. (NASDAQ:RXST) Investors may have been Affected by Fraud – Contact BFA Law by September 22 about Potentially Recovering Losses
NEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against RxSight, Inc. (NASDAQ: RXST) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in RxSight, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/rxsight-inc-class-action-lawsuit.
Neutral
PRNewsWire
23 hours ago
ATTENTION NASDAQ: RXST INVESTORS: Contact Berger Montague About an RxSight Class Action Lawsuit
PHILADELPHIA , July 29, 2025 /PRNewswire/ -- Berger Montague PC , a nationally recognized securities litigation law firm, is investigating potential securities law violations involving RxSight, Inc. ("RxSight" or the "Company") (NASDAQ: RXST). A class action lawsuit was recently filed on behalf of investors who acquired RxSight securities between November 7, 2024 and July 8, 2025 (the "Class Period").
Neutral
PRNewsWire
23 hours ago
RXST INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that RxSight, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
SAN DIEGO , July 29, 2025 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that the RxSight class action lawsuit – captioned Makaveev v. RxSight, Inc., No.
Neutral
GlobeNewsWire
1 day ago
Deadline Alert: RxSight, Inc. (RXST) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
LOS ANGELES, July 29, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming September 22, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired RxSight, Inc. (“RxSight” or the “Company”) (NASDAQ: RXST) securities between November 7, 2024 and July 8, 2025, inclusive (the “Class Period”).
Neutral
PRNewsWire
1 day ago
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RxSight
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In RxSight To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 in RxSight between November 7, 2024 and July 8, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , July 29, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against RxSight, Inc. ("RxSight" or the "Company") (NASDAQ: RXST) and reminds investors of the September 22, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Neutral
PRNewsWire
1 day ago
Shareholders that lost money on RxSight, Inc.(RXST) should contact Levi & Korsinsky about pending Class Action - RXST
NEW YORK , July 29, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in RxSight, Inc. ("RxSight, Inc." or the "Company") (NASDAQ: RXST) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of RxSight, Inc. investors who were adversely affected by alleged securities fraud between November 7, 2024 and July 8, 2025.
Neutral
PRNewsWire
1 day ago
RXST Investors Have Opportunity to Lead RxSight, Inc. Securities Fraud Lawsuit
NEW YORK , July 28, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of RxSight, Inc. (NASDAQ: RXST) between November 7, 2024 and July 8, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed.
Neutral
GlobeNewsWire
2 days ago
ROSEN, LEADING INVESTOR COUNSEL, Encourages RxSight, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – RXST
NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of RxSight, Inc. (NASDAQ: RXST) between November 7, 2024 and July 8, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 22, 2025.
Charts implemented using Lightweight Charts™